It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cyclic adenosine monophosphate (cAMP) is a master regulator of mitochondrial metabolism but its precise mechanism of action yet remains unclear. Here, we found that a dietary saturated fatty acid (FA), palmitate increased intracellular cAMP synthesis through the palmitoylation of soluble adenylyl cyclase in cardiomyocytes. cAMP further induced exchange protein directly activated by cyclic AMP 1 (Epac1) activation, which was upregulated in the myocardium of obese patients. Epac1 enhanced the activity of a key enzyme regulating mitochondrial FA uptake, carnitine palmitoyltransferase 1. Consistently, pharmacological or genetic Epac1 inhibition prevented lipid overload, increased FA oxidation (FAO), and protected against mitochondrial dysfunction in cardiomyocytes. In addition, analysis of Epac1 phosphoproteome led us to identify two key mitochondrial enzymes of the the β-oxidation cycle as targets of Epac1, the long-chain FA acyl-CoA dehydrogenase (ACADL) and the 3-ketoacyl-CoA thiolase (3-KAT). Epac1 formed molecular complexes with the Ca2+/calmodulin-dependent protein kinase II (CaMKII), which phosphorylated ACADL and 3-KAT at specific amino acid residues to decrease lipid oxidation. The Epac1-CaMKII axis also interacted with the α subunit of ATP synthase, thereby further impairing mitochondrial energetics. Altogether, these findings indicate that Epac1 disrupts the balance between mitochondrial FA uptake and oxidation leading to lipid accumulation and mitochondrial dysfunction, and ultimately cardiomyocyte death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Université Paul Sabatier, UMR 1297-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X); University of Gothenburg and Sahlgrenska University Hospital, Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
2 Université Paul Sabatier, UMR 1297-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X)
3 Université Paul Sabatier, UMR 1297-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X); Centre Hospitalier Universitaire de Toulouse Rangueil, Toulouse, France (GRID:grid.411175.7) (ISNI:0000 0001 1457 2980)
4 University of Gothenburg and Sahlgrenska University Hospital, Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582)
5 PHYMEDEXP, Université de Montpellier, CNRS, INSERM, CHRU Montpellier, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X)